Refractory Status Epilepticus (RSE) research hub

A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus

This study is testing a new medicine, ganaxolone, for a severe type of epilepsy called refractory status epilepticus. It's a late-stage trial comparing ganaxolone to a dummy medicine to see if it can stop seizures quickly and safely when other treatments haven't worked.